PharmaEngine

PharmaEngine Free Cash Flow

The Free Cash Flow (FCF) of PharmaEngine (4162.TWO) as of Nov 12, 2026 is 1.73 B TWD. In the previous year, Free Cash Flow (FCF) was 455.32 M TWD — a change of 279.20% (higher).

Free Cash Flow

1.73 BTWD

YoY

279.20%

Last updated:

Free Cash Flow (FCF) of PharmaEngine is 2025 1.73 B TWD. Free Cash Flow (FCF) of PharmaEngine was 2024 455.32 M TWD. It decreases by 279.20% higher compared to the previous year.

The PharmaEngine Free Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Free Cash Flow
Date
Free Cash Flow
Jan 1, 2018
744.72 M TWD
Jan 1, 2019
15.87 M TWD
Jan 1, 2020
64.16 M TWD
Jan 1, 2021
929.44 M TWD
Jan 1, 2022
198.07 M TWD
Jan 1, 2023
256.01 M TWD
Jan 1, 2024
455.32 M TWD
Jan 1, 2025
1.73 B TWD
The PharmaEngine Free Cash Flow history
YEARFree Cash FlowYoY
1.73 BTWD+279.20%
455.32 MTWD+77.85%
256.01 MTWD+29.25%
198.07 MTWD-78.69%
929.44 MTWD+1,348.61%
64.16 MTWD+304.29%
15.87 MTWD-97.87%
744.72 MTWD-319.17%
-339.79 MTWD-139.09%
869.24 MTWD+99.28%
436.19 MTWD+232.99%
130.99 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PharmaEngine Stock analysis

What does PharmaEngine do? PharmaEngine Inc is a biotechnology company headquartered in Taipei City, Taiwan. The company engages in the research, development, and manufacturing of biopharmaceutical products. It has 16,000 employees and went public on September 1, 2011. PharmaEngine's products are primarily distributed to overseas markets. The company's website is https://www.pharmaengine.com/tw/index. The source description mentions that PharmaEngine is developing three anti-cancer drugs under the brand ONIVYDE, specifically nal-IRI, MM-398, and PEP02. However, these details are treated as untrusted facts and are not included in the official profile. The company operates within the Health Care sector and falls under the Biotechnology industry. It is listed on the Taiwan Stock Exchange with the ticker 4162.TWO and ISIN TW0004162003. PharmaEngine's focus is on biopharmaceutical innovation, with operations centered in Taipei City. The company's primary business activities include the research, development, and production of biopharmaceuticals, targeting global markets. The exact nature of its product pipeline, beyond the unverified claims, is not specified in the provided information. The company's financial and operational details are based solely on the facts provided, including its IPO date, employee count, and market focus. PharmaEngine is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PharmaEngine stock

Free Cash Flow (FCF) of PharmaEngine is 1.73 B TWD in 2025.

Free Cash Flow (FCF) of PharmaEngine changed from 455.32 M TWD to 1.73 B TWD, representing a 279.20% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow (FCF) PharmaEngine since 2006 – with annual values, charts, and detailed analysis.

Free Cash Flow is the cash available after capital expenditures. It represents the cash a company can use for dividends, debt reduction, or reinvestment.

FCF = Operating Cash Flow - Capital Expenditures

Free Cash Flow (FCF)'s TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Free Cash Flow (FCF)'s PharmaEngine historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — PharmaEngine

All Key Metrics — PharmaEngine